The classification of cyclooxygenase inhibitors

P. E. Lipsky, S. B. Abramson, L. Crofford, R. N. Dubois, L. S. Simon, L. B.A. Van de Putte

Research output: Contribution to journalEditorial

113 Scopus citations


In summary, precise classification of COX inhibitors has important clinical implications for efficacy and toxicity. However, classification of these agents clinically is difficult because there are insufficient data to predict correlations between biochemical and pharmacologic properties and the clinical effect of a given agent. In any case, specific COX-2 inhibitors are expected to show antiinflammatory and analgesic activities equivalent to those of NSAID, as well as significant reductions in the incidence of the life threatening side effects (i.e., GI bleeding) associated with COX-1 inhibition. The advantages of preferential COX-2 inhibitors may be more subtle and therefore more difficult to verify in clinical trials.

Original languageEnglish (US)
Pages (from-to)2298-2303
Number of pages6
JournalJournal of Rheumatology
Issue number12
StatePublished - Dec 15 1998


ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Cite this

Lipsky, P. E., Abramson, S. B., Crofford, L., Dubois, R. N., Simon, L. S., & Van de Putte, L. B. A. (1998). The classification of cyclooxygenase inhibitors. Journal of Rheumatology, 25(12), 2298-2303.